首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.

Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Neil E,Fleshner

第一单位： Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

作者： Neil E,Fleshner ^[1] ; Rashid K,Sayyid ^[1] ; Aaron R,Hansen ^[2] ; Joseph L K,Chin ^[3] ; Ricardo,Fernandes ^[4] ; Eric,Winquist ^[4] ; Theodorus,van der Kwast ^[5] ; Joan,Sweet ^[5] ; Katherine,Lajkosz ^[6] ; Miran,Kenk ^[1] ; Karen,Hersey ^[1] ; Rosette,Veloso ^[1] ; Doron,Berlin ^[1] ; Jaime O,Herrera-Caceres ^[1] ; Srikala,Sridhar ^[2] ; Madeleine,Moussa ^[7] ; Antonio,Finelli ^[1] ; Robert J,Hamilton ^[1] ; Girish S,Kulkarni ^[1] ; Alexandre R,Zlotta ^[8] ; Anthony M,Joshua ^[9]

作者单位： Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. ^[1] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. ^[2] Department of Surgery, Division of Urology, Western University, London, Ontario, Canada. ^[3] Department of Oncology, Division of Medical Oncology, Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, Ontario, Canada. ^[4] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. ^[5] Department of Biostatistics, University of Toronto, Toronto, Ontario, Canada. ^[6] Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada. ^[7] Department of Surgery, Urology, Sinai Health System, Toronto, Ontario, Canada. ^[8] Kinghorn Cancer Centre, St Vincent's Hospital, Garvan Institute of Medical Research, Sydney, Australia. ^[9]